ArticleTranslational cancer research2025
An immune-related miRNA signature predicts the prognosis in nasopharyngeal carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MicroRNAs (miRNAs) play a significant role in the progression of nasopharyngeal carcinoma (NPC), particularly in relation to immune responses. This study aims to identify immune-related miRNAs that contribute to the development of a prognostic signature for overall survival (OS) in NPC patients. Methods: Differentially expressed miRNAs between NPC and normal nasopharyngeal tissues were identified using GSE70970, GSE32960, and The Cancer Genome Atlas (TCGA)-NPC datasets. Univariate Cox regression analysis was performed to find miRNAs associated with OS. The Least Absolute Shrinkage and Selection Operator algorithm was conducted on the GSE70970 cohort to create a risk signature, stratifying patients into high- and low-risk groups based on the median risk score. Results: The immune-related miRNA signature included six specific miRNAs: hsa-miR-523, hsa-miR-130a, hsa-miR-342-3p, hsa-miR-320b, hsa-miR-1181, and hsa-miR-150. Patients classified into the high-risk score group exhibited poorer prognoses. The prognostic signature demonstrated its significance as an independent predictor of OS. Furthermore, high-risk patients presented distinct gene mutation statuses and increased stemness scores. Conclusions: The developed immune-related miRNA prognostic signature provided an accurate prediction of NPC prognosis. Additionally, the accompanying nomogram offered a practical tool for estimating patient OS, potentially aiding clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.